Evidence map›Paper›PMID 33255624›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Hydrocarbon-Stapled Peptide Based-Nanoparticles for siRNA Delivery.

Matthieu Simon, Nabila Laroui, Marianne Heyraud, Guillaume Laconde, Lamiaa M A Ali, Kevin Bourbiaux, Gilles Subra, Lubomir L Vezenkov, Baptiste Legrand, Muriel Amblard and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Matthieu SimonIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Nabila LarouiIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.ORCID 0000-0002-6125-6515
Marianne HeyraudIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Guillaume LacondeIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Lamiaa M A AliIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.ORCID 0000-0003-1176-5335
Kevin BourbiauxIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Gilles SubraIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Lubomir L VezenkovIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Baptiste LegrandIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Muriel AmblardIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.
Nadir BettacheIBMM, Univ Montpellier, CNRS, ENSCM, 34093 Montpellier, France.ORCID 0000-0001-5426-7024
École Nationale Supérieure de Chimie de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small interfering RNAs (siRNAs) are promising molecules for developing new therapies based on gene silencing; however, their delivery into cells remains an issue. In this study, we took advantage of stapled peptide technology that has emerged as a valuable strategy to render natural peptides more structured, resistant to protease degradation and more bioavailable, to develop short carriers for siRNA delivery. From the pool of stapled peptides that we have designed and synthesized, we identified non-toxic vectors that were able to efficiently encapsulate siRNA, transport them into the cell and induce gene silencing. Remarkably, the most efficient stapled peptide (JMV6582), is composed of only eight amino-acids and contains only two cationic charges.

Indexed as

CPPgene silencingsiRNAStapled peptides

Identifiers

PMID33255624
PMCPMC7760004
OpenAlexW3109761666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.